Circulating insulin-like growth factor I in relation to melanoma risk in the European prospective investigation into cancer and nutrition

Kathryn E. Bradbury, Paul N. Appleby, Sarah J. Tipper, Ruth C. Travis, Naomi E. Allen, Marina Kvaksoff, Kim Overvad, Anne Tjønneland, Jytte Halkjær, Iris Cervenka, Yahya Mahamat-Saleh, Fabrice Bonnet, Rudolf Kaaks, Renée T. Forner, Heiner Boeing, Antonia Trichopoulou, Carlo La Vecchia, Alexander J. Stratigou, Domenico Palli, Sara Grioni, Giuseppe Matullo, Salvatore Panico, Rosario Tunino, Petra H. Peeters, H. Bas Bueno-de-Mesquita, Reza Ghiasvand, Marit B. Veierød, Elisabete Weiderpass, Catalina Bonet, Elena Molina, José M. Huerta, Nerea Larrañaga, Aurelio Barricarte, Susana Merino, Karolin Isakssoon, Tanja Stocks, Ingrid Ljuslinder, Oskar Hemmingssson, Nick Wareham, Kay-Tee Khaw, Marc J. Gunter, Sabina Rinaldi, Konstantinos K. Tsilidis, Dagfinn Aune, Elio Riboli and Timothy J. Key

1Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
2National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand
3Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
4CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France
5Gustave Roussy, Villejuif, France
6Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark
7Danish Cancer Society Research Center, Copenhagen, Denmark
8CHU Rennes, Université de Rennes 1, Rennes, France
9Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany

Key words: melanoma, insulin-like growth factor I, height, EPIC, biomarker, prospective studies

Abbreviations used: ANOVA: Analysis of variance; BMI: body mass index; CI: confidence interval; EPIC: European prospective investigation into cancer and nutrition cohort; ICD-O-3: International classification of disease – oncology – third edition; ICD-10: International classification of disease – 10th edition; IGF-I: Insulin-like growth factor-I; OR: odds ratio; UK: United Kingdom

Grant sponsor: Cancer Research UK; Grant numbers: C570/A1649, C8221/A19170; Grant sponsor: Cancer Res; Grant numbers: 570/A16491; Grant sponsor: Associazione Italiana per la Ricerca sul Cancro; Grant sponsor: Bundesministerium für Bildung und Forschung; Grant sponsor: Cancerfonden; Grant sponsor: Centre International de Recherche sur le Cancer; Grant sponsor: Consiglio Nazionale delle Ricerche; Grant sponsor: County Councils of Skane and Vasterbotten; Grant sponsor: Deutsche Krebshilfe; Grant sponsor: Deutsches Krebsforschungszentrum; Grant sponsor: Directorate-General for Health and Food Safety; Grant sponsor: Dutch Prevention Funds; Grant sponsor: Dutch ZON (Zorg Onderzoek Nederland); Grant sponsor: Health Research Council of New Zealand; Grant sponsor: Health Research Fund; Grant numbers: P113/00061P113/01162, P113/00061; Grant sponsor: Institut Gustave-Roussy; Grant sponsor: Institut National de la Santé et de la Recherche Médicale; Grant sponsor: Krefteforskningsfondet; Grant sponsor: Kreftforeningen; Grant numbers: 6823329; Grant sponsor: Ligue Contre le Cancer; Grant sponsor: LK Research Funds; Grant sponsor: Medical Research Council; Grant numbers: 1000143MR/M012190/1; Grant sponsor: Ministerie van Volksgezondheid, Welzijn en Sport; Grant sponsor: Mutuelle Générale de l’Education Nationale; Grant sponsor: Netherlands Cancer Registry; Grant sponsor: NordForsk; Grant sponsor: Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra; Grant numbers: Murcia (no. 6236), and Navarra (ISCIII RETIC RD06); Grant sponsor: Statistics Netherlands; Grant sponsor: the Hellenic Health Foundation; Grant sponsor: Vetenskapsrådet; Grant sponsor: World Cancer Research Fund; Grant sponsor: Regional Governments of Andalucia, Asturias, Basque Country, Murcia; Grant numbers: 6236; Grant sponsor: Stat Netherlands (The Netherlands); Grant numbers: ERC-2009-AdG 232997; Grant sponsor: Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); German Cancer Aid, German Cancer Res Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy; Grant sponsor: the European Commission; Grant sponsor: Norwegian Cancer Society

DOI: 10.1002/ijc.31854

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

History: Received 7 Jun 2018; Accepted 25 Jul 2018; Online 7 Sep 2018

Correspondence to: Kathryn E Bradbury, National Institute for Health Innovation, School of Population Health, The University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand, E-mail: k Bradbury@auckland.ac.nz, Tel.: +64 93737599, Fax: +64 93731710
Insulin-like growth factor-I (IGF-I) regulates cell proliferation and apoptosis, and is thought to play a role in tumour development. Previous prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including breast and prostate. No prospective study has examined the association between circulating IGF-I concentrations and melanoma risk. A nested case–control study of 1,221 melanoma cases and 1,221 controls was performed in the European Prospective Investigation into Cancer and Nutrition cohort, a prospective cohort of 520,000 participants recruited from 10 European countries. Conditional logistic regression was used to estimate odds ratios (ORs) for incident melanoma in relation to circulating IGF-I concentrations, measured by immunoassay. Analyses were conditioned on the matching factors and further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity and in women only, use of menopausal hormone therapy. There was no significant association between circulating IGF-I concentration and melanoma risk (OR for highest vs lowest fifth = 0.93 [95% confidence interval [CI]: 0.71 to 1.22]). There was no significant heterogeneity in the association between IGF-I concentrations and melanoma risk when subdivided by gender, age at blood collection, BMI, height, age at diagnosis, time between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (Pheterogeneity = 0.078). We found no evidence for an association between circulating concentrations of IGF-I measured in adulthood and the risk of melanoma.
What’s new?
A possible association between the insulin-like growth factor (IGF-I) and the risk of melanoma has been proposed, but with inconclusive results so far. In this prospective study, the authors found no evidence for an association between circulating IGF-I concentrations and melanoma risk. Although details on major risk factors like sun exposure were missing, the large sample size with more than 1000 incident melanoma cases underscores the relevance of the finding.

Introduction
Worldwide there were an estimated 350,000 new cases of melanoma and 60,000 deaths from melanoma in 2015. Exposure to ultraviolet radiation (specifically, intermittent exposure), and phenotypic characteristics such as fairer skin colour, blond or red hair and multiple naevi and freckles are established risk factors for melanoma. There are also other putative or possible risk factors for melanoma including occupational exposure to chemicals and ionising radiation.

Insulin-like growth factor-I (IGF-I) is a polypeptide hormone that stimulates cell division and inhibits apoptosis; it is through these properties that it is thought to play a role in the development and progression of carcinogenesis. Prospective studies have shown that higher circulating concentrations of IGF-I are associated with a higher risk of cancers at specific sites, including the breast, prostate and possibly the thyroid.

Three case–control studies have examined the relationship between circulating IGF-I concentrations and risk of melanoma, but the results were not consistent. One study found an inverse relationship between circulating IGF-I concentration and risk of melanoma, but two studies found an positive association.

The results of case–control studies may be unreliable if the development of melanoma affects circulating IGF-I concentrations, or if bias was introduced in the selection of controls. Given this uncertainty, we examined the association between circulating IGF-I concentrations measured in adulthood and the subsequent risk of melanoma in a case–control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.

Methods
Study population
The study design, including the recruitment, blood collection and follow-up procedures of EPIC has been described previously. Briefly, between 1992 and 2000 approximately 520,000 participants, mostly aged between 35 and 70 years, were recruited from 23 centres in 10 European countries (Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Spain, Sweden and the United Kingdom). Participants provided information on sociodemographic characteristics, dietary intakes and lifestyle factors. The study was approved by the International Agency for Research on Cancer Ethics Committee and local ethics committees in the participating countries. All participants gave written informed consent.

Selection of cases and controls
In most centres, follow-up for cancer incidence and mortality was conducted via record linkage with regional and national registries. In France, Germany and Greece, follow-up was by a combination of methods, including health insurance records, cancer and pathology registries and active follow-up through study subjects and their next-of-kin.

Cases were participants who were diagnosed with incident invasive melanoma of the skin (WHO international classification of diseases-oncology third edition (ICD-O-3) Codes 8,720–8,790, with fifth digit behaviour Code 3 signifying invasive malignancies) during follow-up, and who had donated a blood sample and had not been diagnosed with cancer (except for nonmelanoma skin cancer) at baseline, and had not been diagnosed with other tumours (except nonmelanoma skin cancer) before the melanoma diagnosis. Superficial spreading melanomas were defined as tumours with ICD-O-3 morphology code 8743/3, and nodular melanomas as those with ICD-O-3 morphology code 8721/3. Melanomas of the head and neck were tumours with international classification of diseases 10th edition (ICD-10) site codes C44.0–C44.4, melanomas of the trunk were those with ICD-10 site code C44.5, melanomas of the upper limbs were those with ICD-10 site code C44.6, and melanomas of the lower limbs were those with ICD-10 site code C44.7. Participants were eligible for selection as a control if they had provided a blood sample at baseline, and were alive and without a cancer diagnosis (other than nonmelanoma skin cancer) at the time of the diagnosis of the index case. Randomly chosen controls were matched (1:1) to each case using incidence density sampling. The matching criteria were: study centre, gender, age at blood collection (± 1 year), and date (± 3 months), time of day (± 3 hr), and fasting status (< 3 hr, 3 to 6 hr, > 6 hr) at blood collection. The present study includes 1,221 cases and 1,221 controls (523 male cases and controls; 698 female cases and controls).

Laboratory measurements
Approximately 75% of participants provided a blood sample at recruitment. In most centres whole blood was transported to a local laboratory, processed within 24 hr, and transported...
Table 1. Characteristics of the melanoma cases and controls

|                          | Controls       | Cases        | $p_{\text{difference}}$ |
|--------------------------|----------------|--------------|-------------------------|
|                          | Men            | Women        |                          |
| n                        | 523            | 698          |                         |
| Mean (SD) age at blood collection (years) | 55.1 (8.1)     | 53.9 (9.0)   | *                        |
| Mean (SD) height (cm)    | 175.3 (6.9)    | 162.2 (6.6)  | 0.016                   |
| Mean (SD) BMI (kg/m²)    | 26.2 (3.5)     | 25.3 (4.3)   | 0.948                   |
| Education                |                |              |                         |
| Primary/none             | 35.7 (183)     | 32.3 (218)   | 0.604                   |
| Secondary               | 38.0 (195)     | 49.9 (337)   |                         |
| Degree                  | 26.3 (135)     | 17.8 (120)   |                         |
| Alcohol intake (g/day)   |                |              |                         |
| < 1                     | 9.2 (48)       | 8.7 (45)     | 0.718                   |
| 1–7                     | 26.8 (140)     | 24.0 (125)   |                         |
| 8–19                    | 27.9 (146)     | 29.0 (151)   |                         |
| 20–39                   | 21.8 (114)     | 21.4 (111)   |                         |
| ≥ 40                    | 14.3 (75)      | 16.9 (88)    |                         |
| Smoking status           |                |              |                         |
| Never                   | 34.2 (177)     | 37.0 (190)   | 0.023                   |
| Former                  | 37.1 (192)     | 41.6 (214)   |                         |
| Current                 | 28.8 (149)     | 21.4 (110)   |                         |
| Physical activity        |                |              |                         |
| Inactive                | 20.3 (103)     | 15.6 (79)    | 0.259                   |
| Moderately inactive     | 33.1 (168)     | 34.7 (176)   |                         |
| Moderately active       | 22.1 (112)     | 24.4 (124)   |                         |
| Active                  | 24.6 (125)     | 25.4 (129)   |                         |
| Mean (95% CI) IGF-I concentrations (nmol/L) | 18.2 (17.7–18.6) | 18.2 (17.8–18.6) | 0.912                   |

Int. J. Cancer: **144**, 957–966 (2019) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
to be stored centrally in liquid nitrogen at −196°C at the International Agency for Research on Cancer. In Denmark, all blood samples were stored locally in nitrogen vapour at −150°C, and in Sweden all blood samples were stored in electric freezers at −70°C. In the Oxford cohort, samples were sent at ambient temperature to a central laboratory in Norfolk, UK with a mean transit time of 1.5 days.

IGF-I concentration was measured in serum samples, except for the participants from Norway and Umeå (Sweden), for which citrated plasma and EDTA plasma samples were used, respectively. IGF-I concentration was measured in the Cancer Epidemiology Unit (Oxford, United Kingdom) using the automated IDS-iSYS immunoassay system from Immunodiagnostic Systems Ltd (Tyne & Wear, United Kingdom). Laboratory personnel were blind to the case–control status of the samples and each case–control set was analysed in the same batch, together with duplicate quality control samples. The intra- and inter-assay coefficients of variation were 3.9% and 4.7% at an overall mean concentration of 14.2 nmol/l.

**Statistical analyses**

All statistical analyses were run using Stata version 14.1 (Stata Corp, College Station, TX). Participant characteristics were compared between cases and controls, for men and women separately, using the paired-sample t test for continuous variables and the chi-square test for categorical variables.

IGF-I concentration was logarithmically transformed (using the natural log transformation) to approximate a normal distribution. Among controls only, geometric mean serum IGF-I concentrations by participant characteristics were investigated using analysis of variance (ANOVA), adjusted for batch, age at blood collection (as a continuous variable), gender, country and alcohol intake. Tests for linear trends across categories were performed by scoring categories with consecutive integers. Odds ratios (ORs) and 95% confidence intervals (CIs) for melanoma by quintiles of gender-specific serum IGF-I concentration at baseline (based on the gender-specific distributions in the controls) were estimated using conditional logistic regression, conditioned on the matching variables. In the multivariable model, to allow for finer adjustment for age, the model was adjusted for age at blood collection (in months, as a continuous variable), as well as education (primary/none, secondary, degree), height (gender-specific quartiles), BMI (gender-specific quartiles), smoking status (never, former, current), alcohol intake (<1, 1–7, 8–19, 20–39, ≥40 g/d), marital status (married/cohabiting, unmarried/not cohabiting), physical activity (inactive, moderately inactive, moderately active, active), and in women only, use of menopausal hormone therapy (current, not current). For all covariates, any missing values were assigned to a separate category. The odds of melanoma associated with a doubling of IGF-I concentration were investigated as described above but using the logarithm to the base 2 of serum IGF-I concentration.
Table 2. Adjusted geometric mean IGF-I concentrations (nmol/L) by participant characteristics in 1221 controls

| Characteristic                  | n   | Geometric mean (95% CI) | \( P_{\text{difference}} \) |
|---------------------------------|-----|-------------------------|-----------------------------|
| **Gender**                      |     |                         |                             |
| Men                             | 523 | 18.2 (17.8–18.6)        | 0.002                       |
| Women                           | 698 | 17.3 (17.0–17.7)        |                             |
| **Age at blood collection (years)** |     |                         |                             |
| <50                             | 292 | 20.0 (19.3–20.6)        | <0.001                      |
| 50–54                           | 302 | 17.9 (17.4–18.5)        |                             |
| 55–59                           | 282 | 16.9 (16.4–17.4)        |                             |
| 60–64                           | 207 | 16.8 (16.2–17.5)        |                             |
| \( \geq 65 \)                   | 138 | 15.9 (15.2–16.6)        |                             |
| **Country**                     |     |                         |                             |
| Denmark                         | 258 | 17.3 (16.6–18.1)        | 0.004                       |
| France                          | 49  | 18.5 (17.1–20.1)        |                             |
| Germany                         | 146 | 17.0 (15.9–18.1)        |                             |
| Greece                          | 18  | 16.5 (14.5–18.9)        |                             |
| Italy                           | 110 | 18.3 (17.3–19.4)        |                             |
| Netherlands                     | 109 | 19.5 (18.2–20.9)        |                             |
| Norway                          | 27  | 14.4 (11.8–17.5)        |                             |
| Spain                           | 70  | 17.5 (16.3–18.7)        |                             |
| Sweden                          | 272 | 17.6 (16.5–18.8)        |                             |
| UK                              | 162 | 18.1 (17.2–19.1)        |                             |
| **Education**                   |     |                         |                             |
| Primary/none                    | 401 | 17.3 (16.9–17.8)        | 0.118                       |
| Secondary school                | 532 | 17.8 (17.4–18.2)        |                             |
| Degree                          | 255 | 18.1 (17.5–18.8)        |                             |
| **Height (quartiles)**          |     |                         |                             |
| Lowest quartile                 | 336 | 17.4 (16.9–17.9)        | 0.131                       |
| 2                               | 347 | 17.5 (17.0–18.0)        |                             |
| 3                               | 280 | 18.3 (17.7–18.9)        |                             |
| Highest quartile                | 258 | 17.8 (17.2–18.4)        |                             |
| **BMI (kg/m²)**                 |     |                         |                             |
| Lowest quartile                 | 302 | 17.4 (16.8–17.9)        | 0.036                       |
| 2                               | 315 | 18.2 (17.6–18.7)        |                             |
| 3                               | 306 | 18.0 (17.5–18.6)        |                             |
| Highest quartile                | 298 | 17.3 (16.7–17.8)        |                             |
| **Alcohol intake (g/day)**      |     |                         |                             |
| \(< 1 \)                       | 249 | 18.3 (17.6–18.9)        | 0.023                       |
| 1–7                             | 389 | 18.0 (17.5–18.5)        |                             |
| 8–19                            | 314 | 17.6 (17.1–18.2)        |                             |
| 20–39                           | 176 | 17.2 (16.5–17.9)        |                             |
| \( \geq 40 \)                  | 93  | 16.4 (15.5–17.4)        |                             |
| **Smoking status**              |     |                         |                             |
| Never                           | 546 | 17.5 (17.1–17.9)        | 0.440                       |
| Former                          | 378 | 17.9 (17.4–18.4)        |                             |
| Current                         | 287 | 17.8 (17.2–18.3)        |                             |
Using conditional logistic regression, conditioning on the matching factors and adjusting for the covariates listed above (where relevant), we also examined the association between IGF-I and melanoma subdivided by major participant characteristics: gender, age at blood collection (< 55 years, ≥ 55 years), BMI (< 25 kg/m², ≥ 25 kg/m²), height (gender-specific medians: < 176 cm (men) or < 163 cm (women), ≥ 176 cm (men) or ≥ 163 cm (women)), and age at case diagnosis (< 60 years, ≥ 60 years). In addition, to investigate the possibility of reverse causality we examined the association between IGF-I and melanoma subdivided by time between blood collection and diagnosis (< 4 years, ≥ 4 years). Finally, to explore whether IGF-I may be differentially associated with subtypes of melanoma, we examined the association between IGF-I and melanoma risk in categories of anatomical site (head and neck, trunk, upper limbs, and lower limbs) and histological subtype (superficial spreading and nodular melanoma) of the tumour. For these analyses, controls were assigned to the same category as their matched case. For the BMI subgroup analysis, participants were only included if both the case and matched control had a BMI < 25 kg/m², or if both case and matched control had a BMI ≥ 25 kg/m², with similar rules for the analyses subdivided by height and age at blood collection. Tests for heterogeneity of risk between subgroups were performed using the likelihood ratio test, comparing models with and without the interaction term between the logarithm of circulating IGF-I concentration and the variable of interest. All statistical tests were two-sided, and \( p < 0.05 \) was considered statistically significant.

**Results**

Among men, cases were slightly taller, were more likely to have a university degree, and less likely to be current smokers, compared to the controls. Among women, cases were also slightly taller, but were otherwise similar to controls with regards to the characteristics listed in Table 1. Among the

### Table 2. (Continued)

| Characteristic                     | n  | Geometric mean (95% CI) | \( P \) difference |
|-----------------------------------|----|------------------------|--------------------|
| Physical activity                 |    |                        |                    |
| Inactive                          | 261| 17.8 (17.2–18.4)        | 0.546              |
| Moderately inactive               | 399| 17.7 (17.2–18.2)        |                    |
| Moderately active                 | 271| 17.8 (17.2–18.4)        |                    |
| Active                            | 263| 17.3 (16.7–17.9)        |                    |
| Marital status                    |    |                        |                    |
| Married/co-habiting               | 677| 17.8 (17.5–18.2)        | 0.719              |
| Unmarried/not co-habiting         | 194| 17.7 (17.0–18.4)        |                    |
| Parity                            |    |                        |                    |
| Nulliparous                       | 88 | 17.9 (16.9–18.9)        |                    |
| One                               | 117| 17.5 (16.7–18.4)        | 0.062              |
| Two                               | 286| 16.9 (16.4–17.4)        |                    |
| Three                             | 110| 17.7 (16.9–18.6)        |                    |
| Four or more                      | 51 | 16.0 (14.9–17.2)        |                    |
| Oral contraceptive use            |    |                        |                    |
| Never                             | 289| 17.5 (17.0–18.1)        | 0.351              |
| Ever                              | 390| 17.2 (16.7–17.6)        |                    |
| Menopausal hormone therapy use    |    |                        |                    |
| Not current                       | 546| 17.5 (17.2–17.9)        | 0.011              |
| Current                           | 121| 16.3 (15.6–17.2)        |                    |

Adjusted for batch, age at blood collection, gender, country and alcohol intake unless otherwise stated.

\( \text{\^} \)\( p \) values refer to tests of difference between the logarithm of IGF-I concentration in the separate categories (excluding unknowns) calculated by ANOVA.

\( ^{2} \)Adjusted for batch and age at blood collection.

\( ^{3} \)Adjusted for batch and gender.

\( ^{4} \)Adjusted for batch, age at blood collection and gender.

The quartile ranges for height for men were: 150.00–171.00 cm (Quartile 1), 171.20–176.00 cm (Quartile 2), 176.13–181.00 cm (Quartile 3), and 181.30–195.00 cm (Quartile 4) and for women were: 142.00–158.36 cm (Quartile 1), 158.40–163.00 cm (Quartile 2), 163.08–167.00 cm (Quartile 3) and 167.10–184.00 cm (Quartile 4).

The quartile ranges for BMI for men were: 16.58–23.97 kg/m² (Quartile 1), 24.06–26.01 kg/m² (Quartile 2), 26.02–28.25 kg/m² (Quartile 3), and 28.29–39.58 kg/m² (Quartile 4) and for women were: 15.15–22.19 kg/m² (Quartile 1), 22.22–24.45 kg/m² (Quartile 2), 24.50–27.60 kg/m² (Quartile 3) and 27.62–43.19 kg/m² (Quartile 4).

\( ^{5} \)Adjusted for batch, age at blood collection, gender and country.
To the best of our knowledge, this is the first prospective study to examine circulating concentration of IGF-I measured in adulthood in relation to the risk of melanoma. We found no association overall, or for specific anatomical sites or histological subtypes of melanoma. Furthermore, we found no evidence of heterogeneity in the association between circulating IGF-I concentrations and risk of melanoma by sex, age at blood collection, BMI, height, age at diagnosis, or time between blood collection and diagnosis.

There was no significant association between serum IGF-I concentrations and the risk of melanoma in either the basic model, or in the fully adjusted model, further adjusted for age at blood collection, education, height, BMI, smoking status, alcohol intake, marital status, physical activity, and use of menopausal hormone therapy. In the fully adjusted model, the OR for a doubling in IGF-I concentration was 1.04 (95% CI: 0.84–1.28, \(P_{\text{trend}} = 0.736\)) (Table 3). When we examined the associations in prespecified subgroups, we found no significant differences in associations by gender, age at blood collection, BMI, height, age at diagnosis, or years between blood collection and diagnosis, or by anatomical site or histological subtype of the tumour (\(P_{\text{heterogeneity}} \geq 0.078\), for all subgroups) (Table 4).

Discussion
To the best of our knowledge, this is the first prospective study to examine circulating concentration of IGF-I measured in adulthood in relation to the risk of melanoma. We found no association overall, or for specific anatomical sites or histological subtypes of melanoma. Furthermore, we found no evidence of heterogeneity in the association between circulating IGF-I concentrations and risk of melanoma by sex, age at blood collection, BMI, height, age at diagnosis, or time between blood collection and diagnosis.

Three small case–control studies have examined circulating IGF-I concentrations and risk of melanoma, but the findings were inconsistent.\(^{10–12}\) The reason for the inconsistency in the results of these case–control studies is unclear, but the selection of controls in a case–control study can bias the association between exposure and disease.\(^{13}\) In addition, the results of case–control studies may be influenced by reverse causation bias if the presence of disease affects circulating IGF-I concentrations.

Laboratory work has indicated that the IGF-I axis may play a role in melanoma progression; specifically, studies have reported that IGF-I enhances survival and migration of melanoma cells in vitro.\(^{19,20}\) However, the present large prospective study did not find any relation between circulating IGF-I concentrations and the risk of developing melanoma.

The strengths of our study include the large sample size, and the nested-case control design, which allowed for the collection of blood samples before diagnosis of melanoma. A limitation of our study is that we did not have information on some of the major risk factors for melanoma—sun exposure, skin phototype, or family history of melanoma—and therefore we were unable to adjust for these factors in our analysis. However, these factors would only distort the association of IGF-I with melanoma if they were also associated with circulating IGF-I concentrations. In a previous case–control study, adjusting for number of lifetime blistering sunburns, ability to tan and hair colour did not appreciably alter the association between IGF-I and melanoma risk.\(^{11}\) In addition, in our study we used a single measure of circulating IGF-I concentration, but previous work has shown good reproducibility of
circulating IGF-I concentrations over three (intra-class correlation (ICC) = 0.86), and five (ICC = 0.71) years. Finally, more than 90% of circulating IGF-I is bound to IGF binding protein (IGFBP)-3 and we did not measure IGFBPs in our study. IGFBPs may affect the bioavailability and signalling of IGF-I, but the regulation of IGF-I action by the IGFBPs is complex and not fully characterised.

Prospective studies of breast and prostate cancer, have found positive associations with circulating IGF-I concentrations and cancer risk, that were not changed after adjustment for the predominant binding protein, IGFBP-3.

In conclusion, in this large prospective study, which included a total of 1,221 cases of incident melanoma, we did not find any evidence that circulating IGF-I concentration measured in adulthood was associated with the risk of melanoma.

**Data sharing statement**

For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at http://epic.iarc.fr/access/index.php.

---

**Table 4. Relationship between circulating IGF-I concentration and risk of melanoma, subdivided by participant and tumour characteristics**

|                          | n\_cases/n\_controls | OR (95% CI) for a doubling in IGF-I concentration\(^1\) | P\_trend | P\_heterogeneity |
|--------------------------|-----------------------|------------------------------------------------------|----------|-----------------|
| **Gender**               |                       |                                                      |          |                 |
| Men                      | 523/523               | 1.00 (0.71–1.41)                                     | 0.983    | 0.707           |
| Women                    | 698/698               | 1.04 (0.79–1.38)                                     | 0.760    |                 |
| **Age at blood collection\(^2\)** |                       |                                                      |          |                 |
| ≤ 55 years               | 587/587               | 1.15 (0.82–1.60)                                     | 0.423    | 0.335           |
| ≥ 55 years               | 623/623               | 0.91 (0.68–1.22)                                     | 0.523    |                 |
| **BMI\(^3\)**            |                       |                                                      |          |                 |
| < 25 kg/m\(^2\)          | 315/315               | 1.56 (0.99–2.45)                                     | 0.051    | 0.0131          |
| ≥ 25 kg/m\(^2\)          | 368/368               | 0.88 (0.60–1.28)                                     | 0.496    |                 |
| **Height\(^4\)**         |                       |                                                      |          |                 |
| < 176 cm (men) or < 163 cm (women) | 324/324 | 0.97 (0.65–1.45)                                     | 0.866    | 0.935           |
| ≥ 176 cm (men) or ≥ 163 cm (women) | 347/347 | 0.94 (0.62–1.43)                                     | 0.771    |                 |
| **Age at diagnosis**     |                       |                                                      |          |                 |
| < 60 years               | 513/513               | 1.03 (0.72–1.47)                                     | 0.878    | 0.865           |
| ≥ 60 years               | 708/708               | 0.98 (0.74–1.29)                                     | 0.885    |                 |
| **Time between blood collection and diagnosis** |           |                                                      |          |                 |
| < 4 years                | 361/361               | 0.79 (0.53–1.18)                                     | 0.246    | 0.078           |
| ≥ 4 years                | 860/860               | 1.18 (0.91–1.52)                                     | 0.212    |                 |
| **Tumour characteristics** |                       |                                                      |          |                 |
| **Anatomical site**      |                       |                                                      |          |                 |
| Head and neck            | 125/125               | 0.47 (0.18–1.22)                                     | 0.116    | 0.468           |
| Trunk                    | 400/400               | 1.27 (0.87–1.87)                                     | 0.217    |                 |
| Upper limbs              | 244/244               | 0.89 (0.54–1.48)                                     | 0.651    |                 |
| Lower limbs              | 332/332               | 1.22 (0.80–1.85)                                     | 0.354    |                 |
| **Histological subtype** |                       |                                                      |          |                 |
| Superficial spreading    | 537/537               | 1.01 (0.73–1.40)                                     | 0.942    | 0.249           |
| Nodular melanoma         | 114/114               | 0.57 (0.25–1.29)                                     | 0.175    |                 |

Case and control participants were matched on study centre, gender, age at blood collection (± 1 year) and date (± 3 months), time of day (± 3 hr), and fasting status (< 3 hr, 3 to 6 hr, > 6 hr) at blood collection.

\(^1\)ORs (95% CI) are from conditional logistic regression models conditioned on the matching factors (above) and adjusted for age at blood collection (continuous), height (gender-specific quartiles), BMI (gender-specific quartiles), education (primary/none, secondary, degree, unknown), smoking (never, former, current, unknown), alcohol intake (≤1 g, 1–7 g, 8–19 g, 20–39 g, ≥40 g, unknown), marital status (married/cohabiting, unmarried/not cohabiting, unknown), physical activity (inactive, moderately inactive, moderately active, unknown), and current use of menopausal hormone therapy where appropriate.

\(^2\)Participants were included in the age at blood collection subgroup analysis if both the case and the matched control were aged <55 years, or if both the case and the matched control were aged ≥55 years.

\(^3\)Participants were included in the BMI subgroup analysis if both the case and the matched control had a BMI <25 kg/m\(^2\), or if both the case and the matched control had a BMI ≥25 kg/m\(^2\).

\(^4\)Participants were included in the height subgroup analysis if both the case and the matched control had height < 176 cm (men) or < 163 cm (women), or if both the case and the matched control had height ≥ 176 cm (men) or ≥ 163 cm (women).
References

1. Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the global burden of disease study 2015. Br J Dermatol 2017;177:134–40.
2. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma. II. Sun exposure. Eur J Cancer 2005;41:45–60.
3. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41:2040–59.
4. Berwick M, Buller DB, Cast A, et al. Melanoma epidemiology and prevention. In: Kaufman HL, Mehnert JM (eds) melanoma. Springer international publishing Switzerland. Cancer Treat Res 2016;167:17–49.
5. Fortes C, de Vries E. Nonsolar occupational risk factors for cutaneous melanoma. Int J Dermatol 2008;47:319–28.
6. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915–28.
7. Endogenous Hormones Breast Cancer Collaborative Group, Key TJ, Appleby PN, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010;11:530–42.
8. Travis RC, Appleby PN, Martin RM, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-1 and prostate cancer risk. Cancer Res 2016;76:2288–300.
9. Schmidt JA, Allen NE, Alnquist M, et al. Insulin-like growth factor-I and risk of differentiated thyroid carcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2014;23:976–85.
10. Kucera R, Treskova I, Vrzalova J, et al. Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res 2014;34:5217–20.
11. Park SL, Setiawan VW, Kanetsky PA, et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels with risk of malignant melanoma. Cancer Causes Control 2011;22:1267–75.
12. Santonocito C, Paradisi A, Capizzi R, et al. Insulin-like growth factor-I (CA) repeats are associated with higher melanoma’s Breslow index but not associated with the presence of the melanoma. A pilot study. Clin Chim Acta 2008;390:104–9.
13. Suttor-Tyrrell K. Assessing bias in case-control studies. Proper selection of cases and controls. Stroke 1991;22:938–42.
14. Riboli E, Kaaks R. The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 1997;26(Suppl 1):S6–14.
15. Riboli E, Hunt KJ, Slimani N, et al. European prospective investigation into cancer and nutrition (EPIC) study. Public Health Nutr 2002;5:1113–24.
16. Rothman K, Greenland S, Lash TL. Case-control studies. In: Rothman KJGS, Lash TL, eds Modern epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008. 111–27.
17. Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab 2014;99:1712–21.
18. Wareham NJ, Jakes RW, Rennie KI, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European prospective investigation into cancer and nutrition (EPIC) study. Public Health Nutr 2003;6:407–13.
19. Hilmi C, Larribere L, Giuliano S, et al. IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X (L), and survivin. J Invest Dermatol 2008;128:1499–505.
20. Satyamoorthy K, Li G, Vaidya B, et al. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res 2001;61:7318–24.
21. Missmer SA, Spiegelman D, Bertone-Johnson ER, et al. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomarkers Prev 2006;15:972–8.
22. Borofsky ND, Vogelman JH, Krajcik RA, et al. Utility of insulin-like growth factor-I as a biomarker in epidemiologic studies. Clin Chem 2002;48:2248–51.
23. Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell B 1996;28:619–37.

Acknowledgements

KEB is supported by a Girdlers’ New Zealand Health Research Council Fellowship and the assays were supported by Cancer Res UK (570/A16491). RG is supported by the Norwegian Cancer Society (project 6823329).